DOE Patents title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melonoma

Abstract

A compound for use as a diagnostic or therapeutic pharmaceutical and method of using the same where the compound consists essentially of an alpha-melanotropin stimulating hormone analog which has integrally located a radionuclide. The radionuclide is administered to the body in an amount sufficient to allow uptake and retention by the tumor cells.

Inventors:
; ;
Issue Date:
Research Org.:
Univ. of Missouri, Columbia, MO (United States)
Sponsoring Org.:
USDOE
OSTI Identifier:
1531460
Patent Number(s):
6607709
Application Number:
09/686,700
Assignee:
The Curators of the University of Missouri (Columbia, MO)
Patent Classifications (CPCs):
A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
DOE Contract Number:  
FG02-93ER61661
Resource Type:
Patent
Resource Relation:
Patent File Date: 2000-10-11
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE

Citation Formats

Jurisson, Silvia S., Quinn, Thomas P., and Giblin, Michael F.. Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melonoma. United States: N. p., 2003. Web.
Jurisson, Silvia S., Quinn, Thomas P., & Giblin, Michael F.. Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melonoma. United States.
Jurisson, Silvia S., Quinn, Thomas P., and Giblin, Michael F.. Tue . "Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melonoma". United States. https://www.osti.gov/servlets/purl/1531460.
@article{osti_1531460,
title = {Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melonoma},
author = {Jurisson, Silvia S. and Quinn, Thomas P. and Giblin, Michael F.},
abstractNote = {A compound for use as a diagnostic or therapeutic pharmaceutical and method of using the same where the compound consists essentially of an alpha-melanotropin stimulating hormone analog which has integrally located a radionuclide. The radionuclide is administered to the body in an amount sufficient to allow uptake and retention by the tumor cells.},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = {2003},
month = {8}
}

Works referenced in this record:

Novel metal-binding proteins by design
journal, May 1995


[111In]-DTPA-labeled analogues of α-melanocyte-stimulating hormone for melanoma targeting: Receptor bindingin vitro andin vivo
journal, September 1994


The Design of Metal-Binding Sites in Proteins
journal, June 1993


Tissue sulfhydryl groups
journal, May 1959


Synthesis and copper(II)-binding properties of the N-terminal peptide of human α-fetoprotein
journal, February 1989


Fluorine-18-labeled [Nle4,d-Phe7]-α-MSH, an α-melanocyte stimulating hormone analogue
journal, February 1997


Complexes of technetium-99m with tetrapeptides, a new class of 99mTc-labelled agents
journal, April 1995


Design, Synthesis, and Conformation of Superpotent and Prolonged Acting Melanotropins
journal, May 1993


Restart procedures for the conjugate gradient method
journal, December 1977


The use of a chelating derivative of alpha melanocyte stimulating hormone for the clinical imaging of malignant melanoma
journal, February 1992


Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery.
journal, April 1993


Characterization of the Iron-binding Site in Mammalian Ferrochelatase by Kinetic and Mössbauer Methods
journal, November 1995


Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions
journal, November 1992


Cyclic Melanotropins. 9. 7-D-Phenylalanine Analogues of the Active-Site Sequence
journal, May 1985


Protein Stabilization by Engineered Metal Chelation
journal, October 1991


Synthesis and Characterization of Rhenium-Complexed α-Melanotropin Analogs
journal, May 1997


Specific and stable labeling of antibodies with technetium-99m with a diamide dithiolate chelating agent.
journal, June 1988


Oxo-complexes of rhenium(V)
journal, January 1966


4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity.
journal, October 1980


In situ melanin assay for MSH using mouse B16 melanoma cells in culture
journal, November 1986


Radiolabeled peptides and other ligands for receptors overexpressed in tumor cells for imaging neoplasms
journal, August 1996


Radioreceptor Assay for α;-Msh Using Mouse B16 Melanoma Cells
journal, January 1988


Metalloantibodies
journal, August 1990


Design and characterization of  -melanotropin peptide analogs cyclized through rhenium and technetium metal coordination
journal, October 1998


Influence of α-MSH terminal amino acids on binding affinity and biological activity in melanoma cells
journal, January 1994


Structure proof of syn/anti isomerism in N-alkylated diaminedithiol (DADT) complexes of technetium
journal, October 1990


Recent Developments in Peptide Drug Delivery to the Brain
journal, July 1992


Synthetic analogues of .alpha.-melanotropin
patent, November 1984


A chelating derivative of α-melanocyte stimulating hormone as a potential imaging agent for malignant melanoma
journal, December 1990


    Works referencing / citing this record:

    Metal abstraction peptide with superoxide dismutase activity
    patent, November 2015


    Metal abstraction peptide (MAP) tag and associated methods
    patent, August 2015


    Metal abstraction peptide (MAP) tag and associated methods
    patent, March 2015